BPRCX807

BPRCX 807 is a selective and potent CXCR4 (CXC chemokine receptor type 4) antagonist. BPRCX 807 inhibits CXCL12-mediated ERK and Akt phosphorylation. BPRCX 807 can significantly suppress primary tumor growth. BPRCX 807 can be used for the study of hepatocellular carcinoma[1].

Product Specifications

CAS Number

[2236595-58-5]

UNSPSC

12352005

Target

Akt; CXCR; ERK

Related Pathways

GPCR/G Protein; Immunology/Inflammation; MAPK/ERK Pathway; PI3K/Akt/mTOR; Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

O=C(CNCCC(N1CCC(CC1)NC2=NC(NCC3=NC(CCCNCCCNC4CCCCC4)=CO3)=NC(C)=C2)=O)O

Molecular Formula

C31H51N9O4

Molecular Weight

613.79

References & Citations

[1]Ghasemi K, et al. MSX-122: Is an effective small molecule CXCR4 antagonist in cancer therapy? Int Immunopharmacol. 2022 Jul;108:108863.|[2]Yu SJ, et al. Protective Effect of CXCR4 Antagonist CX807 in a Rat Model of Hemorrhagic Stroke. Int J Mol Sci. 2020 Sep 25;21 (19) :7085.|[3]Song JS, et al. A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment. Proc Natl Acad Sci U S A. 2021 Mar 30;118 (13) :e2015433118.